<DOC>
	<DOC>NCT01892202</DOC>
	<brief_summary>This multicenter observational study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease not on dialysis in routine clinical practice. Eligible patients treated with Mircera for chronic renal anemia according to the standard of care and in line with the current local label will be followed for 6 months.</brief_summary>
	<brief_title>A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patients, 18 to 65 years of age inclusive Patients with chronic kidney disease Stage IIIIV not on dialysis Hb &lt; 10 g/dL (for correction of anemia) or Hb 1012 g/dL and receiving any other ESA (for maintenance of Hb levels) Adequate iron status as judged by the treating physician Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication Significant acute or chronic bleeding Hemoglobinopathies (e.g. homozygous sicklecell disease, thalassemia of all types) Active malignant disease during the last five years (except nonmelanoma skin cancer) Uncontrolled or symptomatic secondary hyperparathyroidism Epileptic seizure during the last 6 months Poorly controlled hypertension (sitting blood pressure &gt; 170/100 mmHG) Myocardial infarction or stroke, or severe or unstable CAD Severe liver disease during the previous 6 months Congestive heart failure NYHA Class IIIIV Diagnosis or suspicion of pure red cell aplasia (PRCA) Planned elective surgery during the study period (except cataract surgery and vascular access surgery) Transfusion of red blood cells during the previous 2 months Pregnant women Any contraindications to Mircera</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>